PURA - Puration Plans To Raise 2020 $8 Million Revenue Target
December 11 2019 - 12:37PM
InvestorsHub NewsWire
Dallas, TX -- December 11, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today confirmed an update with more details on the
company’s recently announced expansion plan scheduled for next week
on Tuesday, December 17, 2019. PURA’s expansion is intended
to substantially increase PURA’s 2020 prospects beyond its current
$8 million revenue target. PURA has recently reconfirmed its
$4 million revenue target for 2019 and an $8 million revenue target
for 2020. The CBD beverage market is one of the fastest
growing beverage sectors anticipated to reach $1.4 billion by
2023.
After introducing its flagship beverage,
EVERx
CBD Sports Water well over two years ago and going on to later
introduce new CBD infused beverages now coming to market, PURA is
taking inventory of its experience and corresponding know-how and
realizing it has amassed resources with the potential to deliver
even more value to shareholders than just supporting the ongoing
growth of its own beverage brands. While the recent business
acquisitions in Europe and Latin American combined with the
business partnerships in Canada and South Africa have expanded the
companies capacity to deliver its own beverages on four different
continents, the acquisitions have also expanded PURA’s capacity to
delivery even more opportunity separate from its current line of
beverages.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024